Mirxes Holding Co. Ltd. announced that its core product, GASTROClear™, has been granted regulatory approval by the National Medical Products Administration of China (NMPA) as a Class III Medical Device for non-invasive gastric cancer screening. GASTROClear™ is the world's first microRNA (miRNA) blood test approved for the early detection of gastric cancer, assessing risk by detecting 12 gastric cancer-associated miRNA biomarkers. This is the first blood test to receive NMPA approval for gastric cancer screening in China. The product will be deployed in both public and private medical institutions across China, significantly expanding Mirxes' reach in the Chinese gastric cancer screening market.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mirxes Holding Co. Ltd. published the original content used to generate this news brief on October 09, 2025, and is solely responsible for the information contained therein.